SuppreMol launched as a new company
SuppreMol is working on the development of drugs for the treatment of autoimmune diseases and allergies through innovative therapeutic approaches centred on Fc -receptors. The development of these drugs is based on patent rights owned by the Max-Planck-Society and licensed to SuppreMol by the Society's Technology Transfer office, Garching Innovation. SuppreMol's principal objective is to prove the therapeutic efficacy of a soluble Fc receptor in the treatment of Idiopathic Thrombocytopenic Purpura, Systemic Lupus Erythematosus, Rheumatoid Arthritis and other autoimmune diseases.
Most read news
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.